<DOC>
	<DOCNO>NCT00086489</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability monoclonal antibody therapy use 2 regimen treatment advance melanoma</brief_summary>
	<brief_title>CP-675,206 In Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm : Stage III ( AJCC 6th edition ) xxl unresectable melanoma , measurable disease ( either locally relapse unresectable , intransit lesion unresectable drain node ) Stage IV melanoma , include : Metastasis skin , subcutaneous tissue distant lymph node , Metastasis lung , Metastasis visceral sit either LDH &lt; = ULN ( upper limit normal ) single site metastasis Note : Patients melanoma ocular origin consider ineligible Documented progressive disease follow adjuvant therapy , localize therapy therapy metastatic disease Measurable disease define least one target lesion accurately measure whose size least 1.0 cm ( spiral CT ) 2.0 cm ( conventional technique ) long diameter ECOG performance status 0 1 Life expectancy &gt; 3 month Either gender , age 18 year Adequate bone marrow , hepatic , renal function determine within 2 week prior start therapy , define : Absolute neutrophil count &gt; = 1.5 x 10 ( 9 ) cells/L Platelets &gt; = 100 x 10 ( 9 ) /L Hemoglobin &gt; = 10 g/dL Aspartate alanine aminotransferase ( AST , ALT ) &lt; = 2.5 x ULN ( &lt; = 5 x ULN , document liver metastasis present ) Total bilirubin &lt; = 1.5 x ULN Creatinine &lt; = 1.5 x ULN Patients must recover prior treatment related toxicity , baseline status , CTC grade 0 1 . Postsurgical pain shall consider basis exclusion . Females must either childbearing potential [ surgically sterilize , include tubal ligation , least 2 year postmenopausal ; breastfeed ] , practice 1 form approve contraception least three month prior entry study 1 follow method : ( ) oral contraceptive , ( b ) intrauterine device , ( c ) implant contraceptive ( Norplant® ) , ( ) inject contraceptive ( DepoProvera® ) , ( e ) diaphragm , ( f ) sexual partner must use condom surgically sterilize , ( g ) sexually inactive . Females childbearing potential must instruct avoid pregnancy study participation . Negative serum urine pregnancy test must document screen evaluation . Must willing able provide write informed consent . Received immunotherapy cancer within one month prior start screen Patients previously treat protocol History , significant evidence risk , chronic inflammatory autoimmune disease ( e.g . Addison 's disease , asthma , celiac disease , multiple sclerosis , Graves Disease , Hashimoto 's thyroiditis , inflammatory bowel disease , psoriasis , rheumatoid arthritis , systemic lupus erythematosus , etc . ) Potential requirement systemic corticosteroid concurrent immunosuppressive drug base prior history . History autoimmune colitis chronic gastrointestinal condition associate diarrhea bleeding , current acute colitis origin . Pregnant lactating woman . Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol . Diagnosed suspected brain metastasis . Patients past history brain metastasis radiologic evidence within 12 week prior enter protocol eligible . Any serious uncontrolled medical disorder active infection , would impair ability receive study treatment . Coexisting malignancy except basal squamous cell carcinoma skin . Received prior CTLA4 inhibiting agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>metastatic melanoma</keyword>
	<keyword>multiple dose</keyword>
</DOC>